MCID: PDT014
MIFTS: 32

Pediatric Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Pediatric Ependymoma

MalaCards integrated aliases for Pediatric Ependymoma:

Name: Pediatric Ependymoma 12 15
Childhood Ependymoma 12
Familial Ependymoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5509
NCIt 49 C8578
UMLS 71 C1851584

Summaries for Pediatric Ependymoma

MalaCards based summary : Pediatric Ependymoma, also known as childhood ependymoma, is related to cellular ependymoma and anaplastic ependymoma. An important gene associated with Pediatric Ependymoma is MAPRE1 (Microtubule Associated Protein RP/EB Family Member 1). The drugs Lenograstim and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and lung, and related phenotypes are Increased proliferation and mortality/aging

Wikipedia : 74 Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to... more...

Related Diseases for Pediatric Ependymoma

Diseases related to Pediatric Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 cellular ependymoma 31.1 RELA MEN1 C11orf95
2 anaplastic ependymoma 29.6 RELA NF2
3 myxopapillary ependymoma 29.2 RELA NF2 KRT75 C11orf95
4 malignant ependymoma 27.9 SEC61G SCHIP1 RELA NF2 NELL2 KRT75
5 benign ependymoma 10.7
6 rela fusion-positive ependymoma 10.2 RELA C11orf95
7 pediatric supratentorial ependymoma 10.0 RELA KRT75 C11orf95
8 rare tumor 10.0
9 meningioma, radiation-induced 10.0
10 meningioma, familial 10.0
11 spinal meningioma 10.0
12 secretory meningioma 10.0
13 lymphoplasmacyte-rich meningioma 10.0
14 neurofibromatosis 10.0
15 tanycytic ependymoma 9.9 NF2 KRT75
16 spinal cord glioma 9.9 NF2 C11orf95
17 brain cancer 9.8
18 malignant glioma 9.8
19 myelitis 9.8
20 cranial nerve palsy 9.8
21 pediatric infratentorial ependymoma 9.8
22 chromosomal triplication 9.8
23 glioma 9.8
24 mollaret meningitis 9.8
25 glial tumor 9.8
26 glioma susceptibility 1 9.8
27 medulloblastoma 9.8
28 paroxysmal extreme pain disorder 9.8
29 familial adenomatous polyposis 9.8
30 hydrocephalus 9.8
31 tic disorder 9.8
32 astrocytoma 9.8
33 mutism 9.8
34 alopecia 9.8
35 brain tumor, childhood 9.8
36 monosomy 22 9.8
37 spinal cancer 9.7 NF2 C11orf95
38 spinal cord ependymoma 9.6 RELA NF2 NELL2 MEN1 C11orf95
39 cerebrum cancer 9.5 RELA NF2 NELL2 KRT75 C11orf95
40 cerebral ventricle cancer 9.5 RELA NF2 NELL2 KRT75 C11orf95
41 supratentorial cancer 9.5 RELA NF2 NELL2 KRT75 C11orf95

Graphical network of the top 20 diseases related to Pediatric Ependymoma:



Diseases related to Pediatric Ependymoma

Symptoms & Phenotypes for Pediatric Ependymoma

GenomeRNAi Phenotypes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 MEN1 NF2

MGI Mouse Phenotypes related to Pediatric Ependymoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 CBY1 DONSON ERCC5 GNAO1 IPO7 JTB

Drugs & Therapeutics for Pediatric Ependymoma

Drugs for Pediatric Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
3
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
8
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11 Antiemetics Phase 3
12 Emetics Phase 3
13 Psychotropic Drugs Phase 2, Phase 3
14 Anticonvulsants Phase 2, Phase 3
15 Podophyllotoxin Phase 3 518-28-5
16 Keratolytic Agents Phase 3
17 Gastrointestinal Agents Phase 3
18 Neurotransmitter Agents Phase 3
19 Histamine Antagonists Phase 3
20 Anti-Allergic Agents Phase 3
21
Histamine Phosphate Phase 3 51-74-1 65513
22 Histamine H1 Antagonists Phase 3
23
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
24
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
25
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
26
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
27
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
28
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
29
Phenylacetic acid Approved Phase 2 103-82-2 999
30
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
31
Carmustine Approved, Investigational Phase 2 154-93-8 2578
32
Sodium citrate Approved, Investigational Phase 2 68-04-2
33
Tamoxifen Approved Phase 2 10540-29-1 2733526
34
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
37
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
38
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
39
Mesna Approved, Investigational Phase 2 3375-50-6 598
40
Etoposide Approved Phase 2 33419-42-0 36462
41
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
42
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
43
Iodine Approved, Investigational Phase 2 7553-56-2 807
44
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
45
leucovorin Approved Phase 2 58-05-9 6006 143
46
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
47
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
48
Promethazine Approved, Investigational Phase 2 60-87-7 4927
49
Acetaminophen Approved Phase 2 103-90-2 1983
50
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
5 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
8 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
9 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
10 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
11 A Phase II Study of Navelbine (Vinorelbine) In Children With Recurrent Or Refractory Malignancies Completed NCT00003234 Phase 2 vinorelbine tartrate
12 A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS Completed NCT00002825 Phase 2 docetaxel
13 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
14 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate
15 A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors Completed NCT00047177 Phase 2 Oxaliplatin
16 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
17 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
18 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
19 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
20 A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
21 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
22 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
23 Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
24 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
25 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
26 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
27 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
28 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
29 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting NCT00602667 Phase 2 Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
30 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus
31 A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma Terminated NCT01032070 Phase 2 erlotinib;etoposide
32 Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205 Terminated NCT01247922 Phase 2 Erlotinib
33 A Phase II Multi-Institutional Trial of Focal Radiotherapy With Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children With Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively Terminated NCT01088035 Phase 2 Carboplatin
34 A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas Terminated NCT00074334 Phase 1, Phase 2
35 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
36 Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
37 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
38 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
39 PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS Completed NCT00002753 Phase 1
40 A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltransferase Completed NCT00005796 Phase 1 lomustine;procarbazine hydrochloride;vincristine sulfate
41 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
42 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
43 Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time Completed NCT00513981 Phase 1 leucovorin calcium;methotrexate
44 Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
45 Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
46 Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors Completed NCT00098761 Phase 1 laromustine
47 Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis Completed NCT00006246 Phase 1 busulfan
48 A Trial of 06-BG and BCNU in Children With CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
49 Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease Completed NCT00025558 Phase 1 carboplatin;temozolomide;thiotepa
50 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1

Search NIH Clinical Center for Pediatric Ependymoma

Genetic Tests for Pediatric Ependymoma

Anatomical Context for Pediatric Ependymoma

MalaCards organs/tissues related to Pediatric Ependymoma:

40
Brain, Liver, Lung, Testes

Publications for Pediatric Ependymoma

Articles related to Pediatric Ependymoma:

(show top 50) (show all 66)
# Title Authors PMID Year
1
Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy. 61
32514542 2020
2
Ependymoma Pediatric Brain Tumor Protein Fingerprinting by Integrated Mass Spectrometry Platforms: A Pilot Investigation. 61
32183175 2020
3
Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. 61
31276586 2019
4
Pediatric ependymoma: GNAO1, ASAH1, IMMT and IPO7 protein expression and 5-year prognosis correlation. 61
31505435 2019
5
3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors. 61
31586101 2019
6
A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. 61
31502040 2019
7
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. 61
30811284 2019
8
Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma. 61
31293971 2019
9
Pediatric ependymoma: current treatment and newer therapeutic insights. 61
30418040 2018
10
Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. 61
30559935 2018
11
Second cancer risk after radiation therapy of ependymoma using the flattening filter free irradiation mode of a linear accelerator. 61
30125453 2018
12
Radical, Staged Approach to Extensive Posterior Fossa Pediatric Ependymoma: 3-Dimensional Operative Video. 61
29029279 2018
13
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. 61
29350470 2018
14
Outcomes following proton therapy for pediatric ependymoma. 61
29239262 2018
15
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. 61
29500084 2018
16
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. 61
29774098 2018
17
Treatment challenges and outcomes for pediatric intracranial ependymoma at a single institution in Iran. 61
29565756 2018
18
Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. 61
29229328 2018
19
The Pediatric Ependymoma Protein Database (PEPD). 61
29124086 2017
20
Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. 61
28371821 2017
21
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. 61
28437838 2017
22
Silencing of DNA repair sensitizes pediatric brain tumor cells to γ-irradiation using gold nanoparticles. 61
28501783 2017
23
Pediatric Ependymoma: A Proteomics Perspective. 61
28387652 2017
24
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. 61
27966655 2016
25
Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. 61
27863964 2016
26
Pediatric Ependymoma. 61
26503805 2016
27
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. 61
27287856 2016
28
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. 61
27104090 2016
29
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. 61
27390862 2016
30
Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. 61
27386327 2016
31
Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. 61
26500028 2015
32
A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. 61
26338418 2015
33
Proton beam therapy for pediatric ependymoma. 61
25754294 2015
34
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. 61
25724157 2015
35
Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. 61
25486598 2015
36
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. 61
25120190 2014
37
Emotional and behavioral functioning after conformal radiation therapy for pediatric ependymoma. 61
24462384 2014
38
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. 61
24077346 2013
39
Endoscopic endonasal transclival approach to a ventral pontine pediatric ependymoma. 61
23992235 2013
40
Ependymoma in children: molecular considerations and therapeutic insights. 61
23615979 2013
41
Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models. 61
22120695 2012
42
Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). 61
22338015 2012
43
Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. 61
22192550 2011
44
Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. 61
21207372 2011
45
Pediatric ependymomas: will molecular biology change patient management? 61
21892086 2011
46
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. 61
21627842 2011
47
Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma. 61
20347495 2010
48
Utility of cerebrospinal fluid cytology in newly diagnosed childhood ependymoma. 61
20463607 2010
49
Telomerase inhibition as a novel therapy for pediatric ependymoma. 61
20184588 2010
50
Immune gene and cell enrichment is associated with a good prognosis in ependymoma. 61
19917695 2009

Variations for Pediatric Ependymoma

Expression for Pediatric Ependymoma

Search GEO for disease gene expression data for Pediatric Ependymoma.

Pathways for Pediatric Ependymoma

GO Terms for Pediatric Ependymoma

Cellular components related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 ZWINT TP53INP1 SEC61G SCHIP1 RELA PBXIP1
2 cytoplasm GO:0005737 9.47 ZWINT TP53INP1 SCHIP1 RELA PBXIP1 NF2

Biological processes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.02 RELA PBXIP1 MEN1 CBY1 C11orf95

Molecular functions related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 8.92 ZWINT RELA MEN1 ERCC5

Sources for Pediatric Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....